A5009354776- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Palliative Care and End-of-Life Issues
- Cancer Genomics and Diagnostics
- Pain Management and Opioid Use
- Melanoma and MAPK Pathways
- Cancer Immunotherapy and Biomarkers
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer survivorship and care
- Pharmacological Effects and Toxicity Studies
- Cancer Treatment and Pharmacology
- Lung Cancer Diagnosis and Treatment
- Statistical Methods in Clinical Trials
- Cancer, Stress, Anesthesia, and Immune Response
- Lung Cancer Research Studies
- Cardiac electrophysiology and arrhythmias
- Bone health and treatments
- Pancreatic and Hepatic Oncology Research
- Cancer-related cognitive impairment studies
- Cancer Research and Treatments
- Bone and Joint Diseases
- Cancer therapeutics and mechanisms
- Health Systems, Economic Evaluations, Quality of Life
- Pediatric Pain Management Techniques
- Biosimilars and Bioanalytical Methods
Emory University
2016-2024
Atlanta VA Medical Center
2017-2024
Winship Cancer Institute
2017-2024
Atlanta Medical Center
2023
Atlanta VA Health Care System
2021-2022
Veterans Health Administration
2020
Tianjin Medical University Cancer Institute and Hospital
2017
Augusta University
2014-2017
The University of Texas MD Anderson Cancer Center
2006-2016
Sarah Cannon
2016
Abstract In vitro, EGFR inhibition, combined with the BRAF inhibitor vemurafenib, causes synergistic cytotoxicity for BRAFV600E metastatic colorectal cancer, further augmented by irinotecan. The safety and efficacy of irinotecan, cetuximab in BRAF-mutated malignancies are not defined. this 3+3 phase I study, patients BRAFV600E-advanced solid cancers received irinotecan escalating doses vemurafenib. Nineteen (18 cancer 1 appendiceal cancer) were enrolled. Three experienced dose-limiting...
Purpose: Most referrals to palliative care and hospice occur late in the trajectory of disease although an earlier intervention could decrease patients' symptom distress. The purpose this study was determine interval between first consult (PC1) death (D) patients diagnosed with advanced cancer (aCA) at our comprehensive center if such has increased over time. Methods: group 2868 consecutive who had their PC1 during a 30-month period. We reviewed charts for information about demographics,...
Patients with hematologic malignancies have reduced and later access to palliative care services (APCS) than do those solid tumors. It is unclear whether these patients develop a high symptom burden at the end of life that requires special interventions. The purposes this retrospective study were determine symptoms are less severe in on APCS severity associated early APCS.We studied records consecutive their first consultation (PC1). We collected information about demographics, cancer type,...
To evaluate the effectiveness of donepezil compared with placebo in cancer patients fatigue as measured by Functional Assessment for Chronic Illness Therapy-Fatigue (FACIT-F).Patients score >or= 4 on a scale 0 to 10 (0 = no fatigue, worst possible fatigue) more than 1 week were included. Patients randomly assigned receive 5 mg or orally every morning 7 days. A research nurse contacted telephone daily assess toxicity and level. All offered open-label during second week. FACIT-F and/or...
Purpose: Alcoholism is a devastating disease that can cause patient and family suffering frequently underdiagnosed. Preliminary studies suggest it associated with increased symptom expression opioid dose escalation. The CAGE questionnaire widely used tool for alcoholism screening. purpose of this study was to determine the frequency characteristics patients who screen positive in palliative care outpatient clinic (PCOC). Methods: We reviewed 665 consecutive charts referred PCOC collected...
Purpose: There is limited information available about the role and effect of a palliative care consultation service (mobile team, MT) in patient care. The purpose this retrospective chart review was to determine characteristics, findings, outcomes patients referred MT comprehensive cancer center thereby gain its setting. Patients Methods: study group 61 consecutive assessed by one during 2-month period. We reviewed their charts for demographic disease features, reasons consultation,...
Recent reports suggest that high doses of methadone may prolong QTc interval and occasionally cause torsades de pointes; however, few these studies involved the palliative care population.The purpose this study was to determine effect initiation on in patients with cancer pain seen at setting.We enrolled 100 prospective study. Patients were followed clinically electrocardiographically for changes baseline, 2, 4, 8 weeks. Contributing factors prolongation such as medications, cardiovascular...
Abstract BACKGROUND: Methadone is an effective and inexpensive opioid for cancer pain treatment. It has been reported as difficult to use in the outpatient setting because of its variable relative potency long half‐life. The purpose this study was determine outcome methadone initiation or rotation treatment settings. METHODS: Chart review done 189 consecutive patients who underwent at authors' palliative care center. Data were collected regarding demographic clinical characteristics,...
Abstract Introduction: We previously showed that select cytokine gene polymorphisms are a significant predictor for pain reported at initial presentation in 446 white patients newly diagnosed with non–small cell lung cancer. This follow-up study explores the extent to which tumor necrosis factor-α (TNF- α-308 G/A), interleukin (IL)-6 −174G/C, and IL-8 −251T/A could explain variability analgesic response among those (n = 140) subsequently referred treatment. Methods: Pain severity (0, no...
Abstract BACKGROUND: Refusal of appropriately indicated do‐not‐resuscitate (DNR) orders may cause harm and distress for patients, families, the medical team. We conducted a retrospective study to determine frequency predictors refusals DNR in advanced cancer patients admitted an acute palliative care unit. METHODS: A total 2538 consecutive admissions were reviewed. Demographic clinical characteristics from 200 with 100 who refused collected, differences between groups determined by...
3511 Background: BRAF V600 mutations, present in 5-10% of patients (pts) with metastatic colorectal cancer (mCRC), are poor prognostic markers and associated a low response to the combination cetuximab (C) irinotecan (I). Vemurafenib (V), an oral kinase inhibitor specific mutated BRAF, demonstrated 5% rate phase I trial pts BRAF-mutated mCRC. In vitro data CRC cell lines has shown that blockade by vemurafenib triggers compensatory activation EGFR. Inhibition EGFR combined results synergistic...
9021 Background: To better understand outcome heterogeneity in pts with KRAS mutant lung cancers, we analyzed the largest multi-institutional database of metastatic adenocarcinomas. Methods: We reviewed data all who consented to LCMC between 2009-2015. Pts known status were included analyses. Mutation along co-mutations obtained clinical outcomes. evaluated baseline characteristics and association overall survival (OS), calculated from date distant metastasis death, a univariate...
e14562 Background: irAE occur as a result of autoimmunity triggered by ICI during cancer treatment. We hypothesize that more patients (pts) will develop any grade if treated with targeting immune and regulatory T-cells (CTLA-4) than those cells without T (PD-1) non-immune having the least pts to (PD-L1). Methods: reviewed all clinical trials (104; 201 arms) reported were published on PubMed or presented at an ASCO meeting (only not PubMed) 2005-2015. 127 arms from 81 met inclusion criteria...